TP53 and colorectal cancer: Another example is nitazoxanide, an FDA-approved antiprotozoal agent which was proved to have dual inhibitory effects on IL-6/JAK2/STAT3 and p53-dependent signaling pathways in colorectal cancer (CRC) cells [163].